Latanoprost/timolol fixed combination in the treatment of primary open-angle glaucoma
https://doi.org/10.21516/2072-0076-2025-18-1-157-162
Abstract
Latanoprost/timolol fixed combination (FCLT) provides clinically significant IOP reduction with a favorable tolerability profile in patients with glaucoma and ocular hypertension inadequately controlled on monotherapy. FCLT provides better IOP control compared to its components, while demonstrating a favorable safety and tolerability profile. FCLT as a single dose evening instillation provides better 24-hour IOP control. FCLT is associated with fewer side effects, more convenient dosing, and lower exposure to preservatives. These advantages have a positive impact on quality of life, compliance, and possibly on the future outcome of glaucoma surgery.
Supporting agencies: The review was prepared with the support of Viatris.
About the Authors
S. Yu. Petrov
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Sergey Yu. Petrov — Dr. of Med. Sci., head of glaucoma department.
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
O. I. Markelova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Oksana I. Markelova — PhD student.
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
References
1. Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013—2018). Expert Opin Ther Pat. 2019; 29 (10): 793—803. doi: 10.1080/13543776.2019.1661992
2. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Cyclooxygenase pathways. Acta Biochim Pol. 2014; 61 (4): 639—49. PMID: 25343148.
3. Нестеров А.П. Глаукома. Москва: Медицина; 1995. [Nesterov A.P. Glaucoma. Moscow: Medicine; 1995 (In Russ.)].
4. Park JH, Yoo C, Chung HW, Kim YY. Effect of prostaglandin analogues on anterior scleral thickness and corneal thickness in patients with primary openangle glaucoma. Sci Rep. 2021; 11 (1): 11098. doi: 10.1038/s41598-021-90696-4
5. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 208-190. doi: 10.1016/j.ophtha.2014.05.013
6. Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol. 1999; 51 (6): 685-94. doi: 10.1211/0022357991772989
7. Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A Systematic review and network meta-analysis. Ophthalmology. 2016; 123 (1): 129-40. doi: 10.1016/j.ophtha.2015.09.005
8. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106 (4): 653-62. doi: 10.1016/s0161-6420(99)90147-1
9. Prum BE, Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology. 2016; 123 (1): P41-P111. doi: 10.1016/j.ophtha.2015.10.053
10. Babic N. Fixed combinations of glaucoma medications. Srp Arh Celok Lek. 2015; 143 (9-10): 626-31. doi: 10.2298/sarh1510626b
11. Machen L, Razeghinejad R, Myers JS. Fixed-combination topical antihypertensive ophthalmic agents. Expert Opin Pharmacother. 2020; 21 (10): 1269-82. doi: 10.1080/14656566.2020.1743264
12. Wang T, Cao L, Jiang Q, Zhang T. Topical medication therapy for glaucoma and ocular hypertension. Front Pharmacol. 2021; 12: 749858. doi: 10.3389/fphar.2021.749858
13. Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020; 19 (11): 1445-60. doi: 10.1080/14740338.2020.1826928
14. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005; 5 (5): 459-63. doi: 10.1097/01.all.0000183112.86181.9e
15. Hollo G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free Prostaglandin Analogs and Prostaglandin/Timolol fixed combinations in the treatment of glaucoma: Efficacy, safety and potential advantages. Drugs. 2018; 78 (1): 39-64. doi: 10.1007/s40265-017-0843-9
16. Zimmerman T.J. Timolol maleate — a new glaucoma medication? Invest Ophthalmol Vis Sci. 1977 Aug; 16 (8): 687-8. PMID: 407171.
17. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018; 96 (3): e277-e84. doi: 10.1111/aos.13568
18. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014; 311 (18): 1901-11. doi: 10.1001/jama.2014.3192
19. Alekseev I.B., Volkova A.V., Alekseeva L.I. Xalacom: possibilities and advantages of the drug in the treatment of patients with glaucoma. Vestnik oftal'mologii. 2022; 138 (5): 119-25 (In Russ.). doi: 10.17116/oftalma2022138051119
20. Zolotaryov A.V., Karlova E.V. About the mechanism of action of the fixed combination of latanoprost and timolol. Ophthalmology reports. 2011; 4 (2): 71—5 (In Russ.).
21. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007; 24 (12): 1007—16. doi: 10.2165/00002512-200724120-00004
22. Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004; 5 (4): 909-21. doi: 10.1517/14656566.5.4.909
23. Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative G. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002; 120 (7): 915-22. doi: 10.1001/archopht.120.7.915
24. Inoue K, Fujimoto T, Higa R, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5 % fixed combination eyedrops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012; 6: 771-5. doi: 10.2147/OPTH.S31085
25. Konstas AG, Pikilidou MI, Tsironi S, et al. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr Eye Res. 2009; 34 (5): 369-77. doi: 10.1080/02713680902850075
26. Stewart WC, Stewart JA, Day D, Sharpe E.D. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003; 81 (3): 242-6. doi: 10.1034/j.1600-0420.2003.00065.x
27. Tabet R, Stewart WC, Feldman R, Konstas AG. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008; 53 Suppl1(S85-92). doi: 10.1016/j.survophthal.2008.08.011
28. Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma. 2009; 18 (9): 652-7. doi: 10.1097/IJG.0b013e31819c49d4
29. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116 (7): 1243-9. doi: 10.1016/j.ophtha.2009.01.036
30. Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7 (9): e45079. doi: 10.1371/journal.pone.0045079
31. Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013; 29 (4): 382-9. doi: 10.1089/jop.2012.0186
32. Webers CA, Beckers HJ, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical beta-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010; 117 (11): 2067-74 e1-6. doi: 10.1016/j.ophtha.2010.03.024
33. Larsson LI. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005 % and timolol 0.5 % in patients with ocular hypertension. J Glaucoma. 2001; 10 (2): 109-14. doi: 10.1097/00061198-200104000-00007
34. Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009; 19 (1): 66-71. doi: 10.1177/112067210901900110
35. Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1998; 236 (8): 577-81. doi: 10.1007/s004170050124
36. Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010; 128 (2): 165-72. doi: 10.1001/archophthalmol.2009.384
37. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005; 123 (7): 898-902. doi: 10.1001/archopht.123.7.898
38. Konstas AG, Lake S, Economou AI, et al. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol. 2006; 124 (11): 1553-7. doi: 10.1001/archopht.124.11.1553
39. Lazaridou MN, Montgomery DM, Ho WO, Jaberoo D. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/ timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Curr Med Res Opin. 2008; 24 (10): 2725-8. doi: 10.1185/03007990802312567
40. Pfeiffer N, European Latanoprost Fixed Combination Study G. A comparison ofthe fixed combination oflatanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240 (11): 893-9. doi: 10.1007/s00417-002-0553-0
41. Astakhov Yu. S., Goziev S. J., Shikhaliev D. J. The influence of unfixed and fixed combination of Timolol 0.5 % and Latanoprost 0.005 % on local and systemic hemodynamics in treatment of patients with POAG. Ophthalmology reports. 2009; 2 (1): 12-7 (In Russ.).
42. Astakhov Yu.S., Loginov G.N., Akopov E.L., Goziev S.D. The value of safity and effectivity of the preparate Ksalakom under treatment of patients with first openangle glaucoma. Avicenna bulletin. 2008; 1 (34): 63-8 (In Russ.).
43. Palmberg P, Kim EE, Kwok KK, Tressler CS, Canada, United States Fixed Combination Latanoprost/Timolol Study G. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010; 20 (4): 708-18. doi: 10.1177/112067211002000411
44. Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005 % / timolol maleate 0.5 % fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004; 88 (10): 1295-8. doi: 10.1136/bjo.2004.043232
45. Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study G. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004; 111 (2): 276-82. doi: 10.1016/j.ophtha.2003.05.019
46. Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006 Mar; 113 (3): 442-5. doi: 10.1016/j.ophtha.2005.11.011
47. Schwenn O, Heckmann B, Guzy C, Miller PJ. Long-term effect of latanoprost/ timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC Ophthalmol. 2010; 10: 21. doi: 10.1186/1471-2415-10-21
48. Apostolova A.S. A comparative study of Xalatan and Xalacom (Pfizer, USA) efficacy in the treatment of pseudoexfoliative glaucoma. Ophthalmology reports. 2013; 6 (3): 71-4 (In Russ.).
49. Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010; 94 (2): 209-13. doi: 10.1136/bjo.2008.155317
50. Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009; 93 (4): 481-5. doi: 10.1136/bjo.2008.147322
51. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995; 102 (12): 1743-52. doi: 10.1016/s0161-6420(95)30798-1
52. Konstas AG, Nakos E, Tersis I, et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002; 133 (6): 753-7. doi: 10.1016/s0002-9394(02)01460-5
53. Takmaz T, Asik S, Kurkcuoglu P, Gurdal C, Can I. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/ timolol maleate combination. Eur J Ophthalmol. 2008; 18 (1): 60-5. doi: 10.1177/112067210801800110
54. Varma R, Hwang LJ, Grunden JW, Bean GW. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/ timolol versus latanoprost or timolol monotherapy. Br J Ophthalmol. 2010; 94 (1): 80-4. doi: 10.1136/bjo.2009.162107
55. Konstas AG, Quaranta L, Mikropoulos DG, et al. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012; 28 (1): 26-32. doi: 10.1089/jop.2011.0081
56. Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/ timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009; 23 (4): 810-8. doi: 10.1038/eye.2008.148
57. Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007; 23 (5): 1025-32. doi: 10.1185/030079907x182149
58. Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004 % / timolol 0.5 % to once-daily latanoprost 0.005 % / timolol 0.5 % in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007; 17 (2): 183-90. doi: 10.1177/112067210701700206
59. Konstas AG, Mikropoulos DG, Embeslidis T, et al. 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/ timolol, fixed combinations in exfoliative glaucoma. Eye (Lond). 2010; 24 (10): 1606-13. doi: 10.1038/eye.2010.100
60. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008; 53 Suppl1(S93-105). doi: 10.1016/j.survophthal.2008.08.004
61. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998; 126 (1): 37-41. doi: 10.1016/s0002-9394(98)00071-3
62. Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol. 2011; 26 (4-5): 285-9. doi: 10.3109/08820538.2011.588650
63. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002; 47 Suppl 1 (S219. doi: 10.1016/s0039-6257(02)00328-4
64. Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (6): 775-80. doi: 10.1007/s00417-009-1036-3
65. Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011; 20 (4): 215-22. doi: 10.1097/IJG.0b013e3181e08121
66. Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29 (6): 357-9. doi: 10.3109/01676830.2010.527028
67. Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013; 8 (5): e61638. doi: 10.1371/journal.pone.0061638
68. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006; 47 (7): 2917-23. doi: 10.1167/iovs.05-1253
69. Kazanova S.Yu. Adverse effects of prostaglandin analogues used in ophthalmological practice. Russian ophthalmological journal. 2021; 14 (2): 85-9 (In Russ.). https://doi.org/10.21516/2072-0076-2021-14-2-85-89
70. Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol. 1997; 8 (2): 55-8. doi: 10.1097/00055735-199704000-00010
Review
For citations:
Petrov S.Yu., Markelova O.I. Latanoprost/timolol fixed combination in the treatment of primary open-angle glaucoma. Russian Ophthalmological Journal. 2025;18(1):157-162. (In Russ.) https://doi.org/10.21516/2072-0076-2025-18-1-157-162
Views:
127
Email this article 